Baxter appoints Ludwig Hantson as president, International

Hantson joins the US-based firm from Novartis

Ludwig Hantson assumes the role of president, international at Baxter International on 3 May. Most recently, he was chief executive, Pharma North America at Novartis.

Hantson will be responsible for leading the company's international operations.

‘Geographic expansion continues to be a key growth driver for Baxter,’ said Baxter chairman and ceo Robert Parkinson. ‘Our global presence and the strength of our local and regional organisations position us to meet the ever increasing demand for healthcare worldwide.’

Hantson has held a variety of senior management positions at Novartis since 2001, including leading the company's specialist pharmaceuticals unit in the US and European pharmaceuticals operations. Prior to Novartis, he spent 13 years at Janssen Pharmaceutica in marketing and clinical r&d roles.

Baxter International Inc, through its subsidiaries, manufactures drugs for haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.

You may also like

Drug Delivery

US FDA approves cardiovascular medicine from Baxter

The premixed format of eptifibatide to treat acute coronary syndrome is the first of its kind available in a flexible container
You need to be a subscriber to read this article.
Click here to find out more.
Training & Education

Updating the Book

Modern methods for modern times
Regulatory

Indian pricing authority to address overcharging by pharma companies

NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Regulatory

Baxter recalls multivitamin powder after glass particles are found

Preliminary investigations point to an isolated event, says MHRA
Containment

Extract delivers 'remarkable service' to an international healthcare company

When any request is received, the After Market department makes every effort to resolve site issues within the shortest possible time frame
Manufacturing

Update on SafeBridge potent compound safety certification programme

The programme provides drug innovators with an independent assessment of a manufacturing company’s ability to safely produce potent APIs and drug products
Regulatory

Myelofibrosis – pacritinib

Myelofibrosis is a chronic, serious and life-threatening disorder of the bone marrow with a median survival of six years - and much less for very high risk patients
Subscribe now